Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 49
Filtrar
2.
Mol Genet Metab Rep ; 15: 69-70, 2018 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-29744303

RESUMO

We discuss two adult siblings who presented with symptoms of myalgia and rhabdomyolysis following exercise with myoglobinuria; genetic testing confirmed carnitine palmitoyltransferase II deficiency and resulted in institution of appropriate crisis management and dietary advice. We explore the phenotypic variability of this commonest fatty oxidation defect that remains under-diagnosed in the adult population and provide clues for early recognition and diagnosis.

3.
JIMD Rep ; 27: 11-5, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-26404458

RESUMO

We report a baby with medium-chain acyl-coenzyme A dehydrogenase (MCAD) deficiency who presented on day 2 with poor feeding and lethargy. She was floppy with hypoglycaemia (1.8 mmol/l) and hyperammonaemia (182 µmol/l). Despite correction of these and a continuous intravenous infusion of glucose at 4.5-6.2 mg/kg/min, she developed generalised tonic clonic seizures on day 3. She also suffered two episodes of pulseless ventricular tachycardia, from which she was resuscitated successfully. Unfortunately, she died on day 5, following a third episode of pulseless ventricular tachycardia. Arrhythmias are generally thought to be rarer in MCAD deficiency than in disorders of long-chain fatty acid oxidation. This is, however, the sixth report of ventricular tachyarrhythmias in MCAD deficiency. Five of these involved neonates and it may be that patients with MCAD deficiency are particularly prone to ventricular arrhythmias in the newborn period. Three of the patients (including ours) had normal blood glucose concentrations at the time of the arrhythmias and had been receiving intravenous glucose for many hours. These cases suggest that arrhythmias can be induced by medium-chain acylcarnitines or other metabolites accumulating in MCAD deficiency. Ventricular tachyarrhythmias can occur in MCAD deficiency, especially in neonates.

4.
JIMD Rep ; 7: 27-9, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-23430491

RESUMO

Liver dysfunction usually accompanies metabolic decompensation in fatty acid oxidation disorders, including carnitine palmitoyltransferase (CPT) Ia deficiency. Typically, the liver is enlarged with raised plasma transaminase activities and steatosis on histological examination. In contrast, cholestatic jaundice is rare, having only been reported in long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency. We report a 3-year-old boy with CPT Ia deficiency who developed hepatomegaly and cholestatic jaundice following a viral illness. No cause for the jaundice could be found, apart from the fatty acid oxidation disorder. Liver histology showed diffuse, predominately macrovesicular steatosis, hepatocellular and canalicular cholestasis but no bile duct paucity or evidence of large duct obstruction. The liver dysfunction resolved in 4-7 weeks.

5.
Can J Public Health ; 99(4): 276-80, 2008.
Artigo em Inglês | MEDLINE | ID: mdl-18767270

RESUMO

BACKGROUND: Medium Chain Acyl-CoA Dehydrogenase (MCAD) Deficiency is an autosomal recessive disorder of fatty acid oxidation, with potential fatal outcome. MCAD deficiency is diagnosed by acylcarnitine analysis on newborn screening blood spot cards by tandem mass spectrometry. Early diagnosis of MCAD and presymptomatic treatment can potentially reduce morbidity and mortality. OBJECTIVES: To evaluate incidence, clinical outcome, biochemical and molecular phenotype of MCAD cases detected in the first three years of newborn screening in British Columbia (BC). METHODS AND RESULTS: Medium chain length acylcarnitines, octanoylcarnitine (C8) and decanoylcarnitine (C10), were measured on newborn screening blood spot cards. Out of 121,000 live births, 17 newborns had C8 values above the screening cut-off of 0.38 umol/L. Ten newborns had elevated C8 on repeat cards and were investigated further. Both C8 and C8/C10 ratios remained abnormal in all confirmed MCAD cases. Positive predictive value of screening was 58% with no false negative results. Seven patients were homozygous for the common c.985A > G MCAD mutation and three others were compound heterozygous for the c.985A > G and a second mutation. Two novel mutations were identified (c.260T > C and c.382T > A). The estimated incidence of MCAD was approximately 1:12,000 live births. Upon frequent feeding and carnitine supplementation, none of the patients had metabolic crises or adverse outcomes. CONCLUSION: Frequency of MCAD in BC is comparable to reports from other newborn screening programs. Persistence of elevated C8 levels and C8/C10 ratios in confirmed MCAD cases suggest that these are sensitive markers for newborn screening. Early detection and treatment have successfully prevented adverse health outcomes in patients with MCAD.


Assuntos
Acil-CoA Desidrogenase/deficiência , Triagem Neonatal , Acil-CoA Desidrogenase/genética , Colúmbia Britânica/epidemiologia , Morte Súbita Cardíaca/epidemiologia , Morte Súbita Cardíaca/prevenção & controle , Feminino , Indicadores Básicos de Saúde , Humanos , Incidência , Recém-Nascido , Erros Inatos do Metabolismo Lipídico/diagnóstico , Erros Inatos do Metabolismo Lipídico/tratamento farmacológico , Erros Inatos do Metabolismo Lipídico/epidemiologia , Erros Inatos do Metabolismo Lipídico/genética , Masculino , Fenótipo , Fatores de Tempo , Resultado do Tratamento
6.
J Med Genet ; 45(1): 55-61, 2008 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-18178636

RESUMO

BACKGROUND: Mitochondrial DNA (mtDNA) mutations are important causes of human genetic disease, with mutations in tRNA genes particularly prevalent. In many patients, mutations are heteroplasmic, affecting a population of mtDNA molecules. Establishing the pathogenicity of homoplasmic mitochondrial tRNA (mt-tRNA) mutations, in which the mutation is present in every mtDNA molecule, is extremely difficult. These mutations must conform to specific pathogenic criteria, documenting unequivocally a functional defect of the mutant mt-tRNA. AIMS: To investigate the pathogenic nature of two homoplasmic mt-tRNA(Thr) deletions, m.15940delT (previously reported as pathogenic) and m.15937delA, by assessing the steady state levels of the mutant mt-tRNA in tissue and cell-line samples from six unrelated families, in which affected individuals were thoroughly investigated for mitochondrial DNA disease on the basis of clinical presentations. Rates of de novo mitochondrial protein synthesis were also examined in control and m.15937delA mutant fibroblasts. RESULTS: Our data strongly suggest that both single nucleotide deletions are neutral polymorphisms; no obvious defects were apparent in either steady state mt-tRNA(Thr) levels or rates of mitochondrial protein synthesis. CONCLUSIONS: These findings have important implications for the investigation of other families with suspected mtDNA disease, in particular the requirement to fulfil strict and established pathogenic criteria in order to avoid misattribution of pathogenicity to mt-tRNA variants.


Assuntos
DNA Mitocondrial/genética , Doenças Mitocondriais/diagnóstico , Doenças Mitocondriais/genética , Mutação , RNA de Transferência de Treonina/genética , RNA/genética , Adulto , Biópsia , Células Cultivadas , Criança , Análise Mutacional de DNA , Feminino , Fibroblastos , Humanos , Lactente , Masculino , Mitocôndrias Cardíacas/genética , Mitocôndrias Musculares/genética , Doenças Mitocondriais/fisiopatologia , Músculo Esquelético , Polimorfismo Genético , RNA Mitocondrial , Pele/citologia
7.
Am J Hum Genet ; 81(6): 1133-43, 2007 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-17999356

RESUMO

Very-long-chain acyl-coenzyme A dehydrogenase (VLCAD) deficiency is an inborn mitochondrial fatty-acid beta-oxidation (FAO) defect associated with a broad mutational spectrum, with phenotypes ranging from fatal cardiopathy in infancy to adolescent-onset myopathy, and for which there is no established treatment. Recent data suggest that bezafibrate could improve the FAO capacities in beta-oxidation-deficient cells, by enhancing the residual level of mutant enzyme activity via gene-expression stimulation. Since VLCAD-deficient patients frequently harbor missense mutations with unpredictable effects on enzyme activity, we investigated the response to bezafibrate as a function of genotype in 33 VLCAD-deficient fibroblasts representing 45 different mutations. Treatment with bezafibrate (400 microM for 48 h) resulted in a marked increase in FAO capacities, often leading to restoration of normal values, for 21 genotypes that mainly corresponded to patients with the myopathic phenotype. In contrast, bezafibrate induced no changes in FAO for 11 genotypes corresponding to severe neonatal or infantile phenotypes. This pattern of response was not due to differential inductions of VLCAD messenger RNA, as shown by quantitative real-time polymerase chain reaction, but reflected variable increases in measured VLCAD residual enzyme activity in response to bezafibrate. Genotype cross-analysis allowed the identification of alleles carrying missense mutations, which could account for these different pharmacological profiles and, on this basis, led to the characterization of 9 mild and 11 severe missense mutations. Altogether, the responses to bezafibrate reflected the severity of the metabolic blockage in various genotypes, which appeared to be correlated with the phenotype, thus providing a new approach for analysis of genetic heterogeneity. Finally, this study emphasizes the potential of bezafibrate, a widely prescribed hypolipidemic drug, for the correction of VLCAD deficiency and exemplifies the integration of molecular information in a therapeutic strategy.


Assuntos
Acil-CoA Desidrogenase de Cadeia Longa/deficiência , Acil-CoA Desidrogenase de Cadeia Longa/genética , Bezafibrato/uso terapêutico , Hipolipemiantes/uso terapêutico , Erros Inatos do Metabolismo Lipídico/genética , Acil-CoA Desidrogenase de Cadeia Longa/química , Acil-CoA Desidrogenase de Cadeia Longa/metabolismo , Animais , Células Cultivadas , Ácidos Graxos/metabolismo , Fibroblastos/citologia , Fibroblastos/efeitos dos fármacos , Fibroblastos/enzimologia , Fibroblastos/patologia , Terapia Genética/métodos , Genótipo , Humanos , Erros Inatos do Metabolismo Lipídico/enzimologia , Modelos Moleculares , Reação em Cadeia da Polimerase , RNA Mensageiro/genética , Ratos , Pele/citologia , Pele/enzimologia , Pele/patologia
8.
J Inherit Metab Dis ; 30(1): 23-8, 2007 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-17186413

RESUMO

We report nine new patients with malonic aciduria associated with enzyme-confirmed malonyl-CoA decarboxylase (MCD) deficiency in eight. Clinical details were available on eight, and molecular genetic characterization was obtained for nine. As for 15 previously described patients, cardinal clinical manifestations included developmental delay and cardiomyopathy; metabolic perturbations (e.g. acidosis) and seizures, however, were infrequent or not observed in our patients. For all, detection of elevated malonic acid in urine (+/- increased C3DC acylcarnitine by analysis employing tandem mass spectrometry) led to pursuit of enzyme studies. MCD activities (nmol/h PER mg protein) revealed: control (n = 22), 16.2 +/- 1.8 (SEM; range 5.7-46.2); patients (n = 8, assayed in duplicate), 1.7 +/- 0.3 (10% of parallel control; range 0.6-2.8). Molecular characterization by DNA sequence analysis and multiplex ligation-dependent probe amplification revealed nine novel mutations (c.796C>T; p.Gln266X, c.481delC; p.Leu161CysfsX18, c.1367A>C; p.Tyr456Ser, c.1319G>T; p.Ser440Ile, c.1430C>T; p.Ser477Phe, c.899G>T; p.Gly300Val, c.799-1683_949-1293del3128, and two other large genomic deletions comprising exons 1 or the complete gene) and two known mutations in the MLYCD gene. Our findings increase the number of enzyme-confirmed MCD-deficient patients by >50%, and expand our understanding of the phenotypic and molecular heterogeneity of this rare disorder.


Assuntos
Carboxiliases/deficiência , Carboxiliases/genética , Erros Inatos do Metabolismo/diagnóstico , Erros Inatos do Metabolismo/genética , Mutação , Adolescente , Criança , Pré-Escolar , Éxons , Feminino , Deleção de Genes , Humanos , Lactente , Masculino , Malonatos/urina , Erros Inatos do Metabolismo/sangue , Modelos Biológicos , Modelos Genéticos , Fenótipo , Reação em Cadeia da Polimerase
9.
J Inherit Metab Dis ; 30(1): 104, 2007 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-17160614

RESUMO

We report a patient with carnitine palmitoyltransferase I (CPT I) deficiency, who presented with acute encephalopathy at 6 months of age. This was precipitated by an episode of gastroenteritis. No hypoglycaemia was documented, but there was hepatomegaly; blood tests revealed raised transaminases, a coagulopathy and severe hypertriglyceridaemia (48.8 mmol/L) and hypercholesterolaemia (9.5 mmol/L). The hyperlipidaemia resolved within 3 days of treatment and did not recur. At 2 years of age, the patient's liver function, growth and development are all normal. Hyperlipidaemia has been reported during acute illness in previous patients with CPT I deficiency but it is not a well-recognized feature; it should alert metabolic specialists to this potential diagnosis.


Assuntos
Carnitina O-Palmitoiltransferase/deficiência , Hiperlipidemias/complicações , Hiperlipidemias/diagnóstico , Hiperlipidemias/enzimologia , Erros Inatos do Metabolismo/complicações , Encefalopatias/diagnóstico , Pré-Escolar , Humanos , Erros Inatos do Metabolismo/diagnóstico
10.
J Inherit Metab Dis ; 29(5): 627-30, 2006 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-16865412

RESUMO

Carnitine transporter defect (CTD) is an autosomal recessive disorder characterized by episodes of non-ketotic hypoglycaemia, hyperammonaemia and liver disease, or by the development of cardiomyopathy, both of which occur in infancy and childhood. Blood carnitine concentrations are extremely low. The diagnosis can be confirmed by finding abnormal fat oxidation and carnitine uptake in skin fibroblasts. The condition has not previously been thought to present later in life or to be benign. We report the identification of four women discovered to have CTD as a consequence of finding low carnitine concentrations in the cord blood or newborn samples from their infants. All four mothers had been asymptomatic and none had a cardiomyopathy.


Assuntos
Carnitina/análogos & derivados , Carnitina/metabolismo , Erros Inatos do Metabolismo/diagnóstico , Erros Inatos do Metabolismo/genética , Proteínas de Transporte de Cátions Orgânicos/genética , Adulto , Carnitina/sangue , Consanguinidade , Feminino , Sangue Fetal/metabolismo , Humanos , Recém-Nascido , Masculino , Espectrometria de Massas , Mães , Proteínas de Transporte de Cátions Orgânicos/fisiologia , Oxigênio/metabolismo , Membro 5 da Família 22 de Carreadores de Soluto
11.
Eur J Paediatr Neurol ; 10(2): 78-82, 2006 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-16567117

RESUMO

BACKGROUND: Mitochondrial diseases are an important group of neurometabolic disorders in children with varied clinical presentations and diagnosis that can be difficult to confirm. AIM: To report the significance of reduced respiratory chain enzyme (RCE) activity in muscle biopsy samples from children. METHODS: Retrospective odds ratio was used to compare clinical and biochemical features, DNA studies, neuroimaging, and muscle biopsies in 18 children with and 48 without reduced RCE activity. RESULTS: Children with reduced RCE activity were significantly more likely to have consanguineous parents, to present with acute encephalopathy and lactic acidaemia and/or within the first year of life; to have an axonal neuropathy, CSF lactate >4 mmol/l; and/or to have signal change in the basal ganglia. There were positive associations with a maternal family history of possible mitochondrial cytopathy; a presentation with failure to thrive and lactic acidaemia, ragged red fibres, reduced fibroblast fatty acid oxidation and with an abnormal allopurinol loading test. There was no association with ophthalmic abnormalities, deafness, epilepsy or myopathy. CONCLUSION: The association of these clinical, biochemical and radiological features with reduced RCE activity suggests a possible causative link.


Assuntos
Complexo de Proteínas da Cadeia de Transporte de Elétrons/metabolismo , Doenças Mitocondriais/complicações , Doenças Mitocondriais/diagnóstico , Músculos/enzimologia , Adolescente , Fatores Etários , Encéfalo/patologia , Estudos de Casos e Controles , Criança , Pré-Escolar , Consanguinidade , Feminino , Humanos , Lactente , Ácido Láctico/metabolismo , Masculino , Doenças Mitocondriais/enzimologia
12.
J Inherit Metab Dis ; 28(5): 673-9, 2005.
Artigo em Inglês | MEDLINE | ID: mdl-16151897

RESUMO

We describe two unrelated cases of ornithine aminotransferase (OAT) deficiency with rare neonatal presentation of hyperammonaemia. The diagnosis in the neonatal presentation of OAT deficiency is hampered as hyperornithinaemia is absent. Enzyme and mutation studies confirmed the diagnosis. OAT deficiency should be included in differential diagnosis of neonatal hyperammonaemia.


Assuntos
Erros Inatos do Metabolismo dos Aminoácidos/diagnóstico , Ornitina-Oxo-Ácido Transaminase/deficiência , Amônia/sangue , Arginina/sangue , Citrulina/sangue , Diagnóstico Diferencial , Feminino , Fibroblastos/metabolismo , Glutamina/sangue , Humanos , Hiperamonemia/sangue , Hiperamonemia/diagnóstico , Recém-Nascido , Masculino , Mutação , Triagem Neonatal , Ornitina/sangue , Ácido Orótico/sangue
13.
Br J Dermatol ; 153(1): 11-7, 2005 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-16029320

RESUMO

Germline heterozygous loss-of-function mutations of fumarate hydratase (FH) predispose to the autosomal dominant syndrome of multiple cutaneous and uterine leiomyomatosis (MCUL). Forty-five distinct FH mutations have been identified in 76 of 89 (85%) reported probands with skin leiomyomas. This suggests that MCUL is a genetically homogeneous condition and that most patients presenting with skin leiomyomas will have underlying FH mutations. FH mutations identified include 26/45 (58%) missense; 12/45 (27%) frameshift, 4/45 (9%) nonsense changes and 3/45 (7%) different whole gene deletions. In MCUL kindreds, the majority of females with FH mutations have both skin and uterine leiomyomas. A proportion of individuals with FH mutations have associated renal cancer, a variant known as hereditary leiomyomatosis and renal cell cancer (HLRCC). If selection bias is removed, the prevalence of renal cancer in MCUL lies between one of 46 (2%) families who were not radiologically screened, and two of 32 (6%) families who were radiologically screened. Truncating, particularly frameshift, mutations appear to be significantly associated with renal cancer (P = 0.003), suggesting a possible basis for selective screening. There may also be a significantly increased rate of renal cancer in females (P = 0.004), suggesting a possible role for hormonal factors. Review of the literature suggests that, unlike most individuals presenting with skin leiomyomas, the majority of patients presenting with uterine leiomyomas or renal cancer will not have underlying FH mutations.


Assuntos
Fumarato Hidratase/genética , Leiomioma/genética , Mutação , Síndromes Neoplásicas Hereditárias/genética , Neoplasias Cutâneas/genética , Feminino , Predisposição Genética para Doença , Humanos , Neoplasias Renais/genética , Neoplasias Uterinas/genética
14.
Hum Mol Genet ; 14(15): 2231-9, 2005 Aug 01.
Artigo em Inglês | MEDLINE | ID: mdl-15987702

RESUMO

The nuclear-encoded Krebs cycle enzymes, fumarate hydratase (FH) and succinate dehydrogenase (SDHB, -C and -D), act as tumour suppressors. Germline mutations in FH predispose individuals to leiomyomas and renal cell cancer (HLRCC), whereas mutations in SDH cause paragangliomas and phaeochromocytomas (HPGL). In this study, we have shown that FH-deficient cells and tumours accumulate fumarate and, to a lesser extent, succinate. SDH-deficient tumours principally accumulate succinate. In situ analyses showed that these tumours also have over-expression of hypoxia-inducible factor 1alpha (HIF1alpha), activation of HIF1alphatargets (such as vascular endothelial growth factor) and high microvessel density. We found no evidence of increased reactive oxygen species in our cells. Our data provide in vivo evidence to support the hypothesis that increased succinate and/or fumarate causes stabilization of HIF1alpha a plausible mechanism, inhibition of HIF prolyl hydroxylases, has previously been suggested by in vitro studies. The basic mechanism of tumorigenesis in HPGL and HLRCC is likely to be pseudo-hypoxic drive, just as it is in von Hippel-Lindau syndrome.


Assuntos
Fumarato Hidratase/genética , Mutação em Linhagem Germinativa , Succinato Desidrogenase/genética , Succinato Desidrogenase/metabolismo , Carcinoma de Células Renais/metabolismo , Ciclo do Ácido Cítrico/fisiologia , Feminino , Fumarato Hidratase/metabolismo , Humanos , Leiomioma/genética , Leiomioma/metabolismo , Neoplasias/genética , Neoplasias/metabolismo , Paraganglioma/genética , Paraganglioma/metabolismo , Células Tumorais Cultivadas , Fator A de Crescimento do Endotélio Vascular/metabolismo
15.
J Inherit Metab Dis ; 28(4): 533-44, 2005.
Artigo em Inglês | MEDLINE | ID: mdl-15902556

RESUMO

General mitochondrial trifunctional protein (TFP) deficiency leads to a wide clinical spectrum of disease ranging from severe neonatal/infantile cardiomyopathy and early death to mild chronic progressive sensorimotor poly-neuropathy with episodic rhabdomyolysis. Isolated long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency resulting from the common Glu510Gln mutation usually gives rise to a moderately severe phenotype with multiorgan involvement with high morbidity and mortality. However, isolated LCHAD deficiency can also be consistent with long-term survival in patients identified and treated from an early age. We present biochemical, clinical and mutation data in 9 patients spanning the full spectrum of disease. Fibroblast acylcarnitine profiling shows good correlation with clinical phenotype using the ratio C18(OH)/(C14(OH)+C12(OH)). This ratio shows a gradation of values, from high in four patients with severe neonatal disease (2.5+/-0.8), to low in two neuromyopathic patients (0.35, 0.2). Fibroblast fatty acid oxidation flux assays also show correlation with the patient phenotype, when expressed either as percentage residual activity with palmitate or as a ratio of percentage activity of myristate/oleate (M/O ratio). Fibroblasts from four patients with severe neonatal disease gave an M/O ratio of 4.0+/-0.6 compared to 1.97 and 1.62 in two neuromyopathic patients. Specific enzyme assay of LCHAD and long-chain 3-ketothiolase activity in patient cells shows lack of correlation with phenotype. These results show that measurements in intact cells, which allow all determinative and modifying cellular factors to be present, better reflect patient phenotype. Mutation analysis reveals a number of alpha- and beta-subunit mutations. Peripheral sensorimotor polyneuropathy, often as the initial major presenting feature but usually later accompanied by episodic rhabdomyolysis, is a manifestation of mild TFP protein deficiency. The mild clinical presentation and relative difficulty in diagnosis suggest that this form of TFP is probably underdiagnosed.


Assuntos
Acil-CoA Desidrogenase de Cadeia Longa/deficiência , Erros Inatos do Metabolismo Lipídico/diagnóstico , Erros Inatos do Metabolismo Lipídico/genética , Mitocôndrias/patologia , Complexos Multienzimáticos/deficiência , Cardiomiopatias/diagnóstico , Cardiomiopatias/genética , Carnitina/análogos & derivados , Carnitina/metabolismo , Éxons , Ácidos Graxos/metabolismo , Fibroblastos/metabolismo , Homozigoto , Humanos , Masculino , Proteína Mitocondrial Trifuncional , Mutação , Fenótipo , Polineuropatias/diagnóstico , Polineuropatias/genética , Prognóstico , Rabdomiólise/diagnóstico , Rabdomiólise/genética
16.
Neuropediatrics ; 35(5): 312-6, 2004 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-15534767

RESUMO

Two unusual cases of axonal neuropathy associated with short-chain acyl-CoA dehydrogenase (SCAD) deficiency are described. These two unrelated infants presented with profound generalised weakness, particularly affecting the upper limbs. Clinical examination revealed generalised peripheral hypotonia and weakness, with absent deep tendon reflexes. An axonal polyneuropathy was confirmed on electromyogram (EMG) and nerve conduction studies (NCS) and, following an extensive metabolic screen, an acylcarnitine and organic acid profile consistent with a short-chain fatty acid beta-oxidation defect was found. In both cases, SCAD deficiency was confirmed by enzyme analysis. Genetic analysis showed the presence of common gene variations in the SCAD gene. SCAD deficiency is a rare disorder with a wide clinical phenotype. SCAD deficiency associated with axonal neuropathy has not previously been reported. As highlighted in these cases, it may be necessary to include axonal neuropathy as a presenting feature of SCAD.


Assuntos
Axônios , Butiril-CoA Desidrogenase/deficiência , Polineuropatias/etiologia , Idade de Início , Humanos , Lactente , Masculino , Debilidade Muscular/etiologia
17.
J Inherit Metab Dis ; 27(4): 473-6, 2004.
Artigo em Inglês | MEDLINE | ID: mdl-15303004

RESUMO

The truncating R254X mutation in the OCTN2 gene results in defective high-affinity carnitine transport and has been previously described as a founder mutation in the Chinese population. We now report a Saudi Arabian kindred with this same mutation, suggesting that it may be a recurrent mutation or a very ancient founder mutation. Western blot analysis of skin fibroblast lysates from the proband with our specific anti-murine OCTN2 antibody revealed the absence of the OCTN2 protein.


Assuntos
Mutação , Proteínas de Transporte de Cátions Orgânicos/genética , Western Blotting , Pré-Escolar , DNA/análise , Feminino , Fibroblastos/química , Humanos , Proteínas de Transporte de Cátions Orgânicos/deficiência , Arábia Saudita , Membro 5 da Família 22 de Carreadores de Soluto
18.
Eur J Paediatr Neurol ; 8(4): 217-9, 2004.
Artigo em Inglês | MEDLINE | ID: mdl-15261886

RESUMO

Blood spot carnitine profiles are widely used to screen for disorders of fatty acid oxidation. This case report emphasizes that a borderline concentration of free carnitine does not exclude the diagnosis of primary carnitine deficiency. Concurrent measurement of carnitine in the plasma and urine is a more sensitive test.


Assuntos
Cardiomiopatia Dilatada/etiologia , Carnitina/deficiência , Cardiomiopatia Dilatada/diagnóstico , Cardiomiopatia Dilatada/genética , Carnitina/sangue , Aberrações Cromossômicas , Diagnóstico Diferencial , Ecocardiografia , Feminino , Genes Recessivos , Humanos , Lactente , Proteínas de Transporte de Cátions Orgânicos/deficiência , Proteínas de Transporte de Cátions Orgânicos/genética , Membro 5 da Família 22 de Carreadores de Soluto
19.
J Inherit Metab Dis ; 27(5): 671-8, 2004.
Artigo em Inglês | MEDLINE | ID: mdl-15669683

RESUMO

We report a patient with lipid-storage myopathy due to multiple acyl-CoA dehydrogenation deficiency (MADD). Molecular genetic analysis showed that she was compound heterozygous for mutations in the gene for electron transfer flavoprotein:ubiquinone oxidoreductase (ETFQO). Despite a good initial response to treatment, she developed respiratory insufficiency at age 14 years and has required long-term overnight ventilation. Thus, MADD is one of the few conditions that can cause a myopathy with weakness of the respiratory muscles out of proportion to the limb muscles.


Assuntos
Acil-CoA Desidrogenases/genética , Flavoproteínas Transferidoras de Elétrons/genética , Proteínas Ferro-Enxofre/genética , Erros Inatos do Metabolismo Lipídico/diagnóstico , Erros Inatos do Metabolismo Lipídico/genética , Metabolismo dos Lipídeos , Doenças Musculares/genética , Mutação , Oxirredutases atuantes sobre Doadores de Grupo CH-NH/genética , Acil-CoA Desidrogenases/deficiência , Adolescente , Idade de Início , Sequência de Bases , Western Blotting , Análise Mutacional de DNA , DNA Complementar/metabolismo , Complexo I de Transporte de Elétrons/deficiência , Complexo I de Transporte de Elétrons/genética , Flavoproteínas Transferidoras de Elétrons/metabolismo , Feminino , Fibroblastos/metabolismo , Heterozigoto , Humanos , Modelos Genéticos , Dados de Sequência Molecular , Doenças Musculares/diagnóstico , Fenótipo , Respiração Artificial
20.
J Inherit Metab Dis ; 26(6): 543-57, 2003.
Artigo em Inglês | MEDLINE | ID: mdl-14605500

RESUMO

Carnitine palmitoyltransferase type II (CPT II) deficiency has three basic phenotypes, late-onset muscular (mild), infantile/juvenile hepatic (intermediate) and severe neonatal. We have measured fatty acid oxidation and CPT II activity and performed mutation studies in 24 symptomatic patients representing the full clinical spectrum of disease. Severe and intermediate phenotypes show a clear correlation with biochemical indices and genetic analysis revealed causative mutations in most patients. Studies of mild phenotypes suggest a more complex interaction, with higher residual fatty acid oxidation, a wider range of CPT II activity (10-60%) but little evidence of genotype-phenotype correlation. Residual CPT II mutant protein from myopathic patients shows thermal instability at 41 degrees C. The common 'polymorphisms' V3681 and M647V are strikingly overrepresented in the myopathic patients, the implication being that they may significantly influence the manifestation of clinical disease and could therefore potentially be considered as a susceptibility variants. Among myopathic individuals, males comprised 88% of patients, suggesting increased susceptibility to clinical disease. A small number of symptomatic patients appear to have significant residual CPT II activity (42-60%) The synergistic interaction of partial deficiencies of CPT II, muscle adenosine monophosphate deaminase and possibly other enzymes of muscle energy metabolism in the aetiology of episodic myopathy deserves wider consideration.


Assuntos
Carnitina O-Palmitoiltransferase/deficiência , Carnitina O-Palmitoiltransferase/genética , Erros Inatos do Metabolismo Lipídico/enzimologia , Erros Inatos do Metabolismo Lipídico/genética , AMP Desaminase/metabolismo , Adolescente , Adulto , Linhagem Celular , Criança , Pré-Escolar , Feminino , Fibroblastos/metabolismo , Genótipo , Humanos , Lactente , Recém-Nascido , Masculino , Mutação/genética , Mutação/fisiologia , Oxirredução , Palmitatos/metabolismo , Polimorfismo Genético/genética , Temperatura
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA